All Access

Biotech Deals

Biotech Deals Alert

Alert

Israeli investment firm Arkin Capital has closed its third biotech venture fund at $100 million, managing partner Pini Orbach tells Axios Pro.

Why it matters: Funds in the sector largely called 2025 a notoriously difficult fundraising year.

Zoom in: Arkin's new fund will invest in 10 to 12 pre-clinical and clinical-stage biotech companies developing therapies across a range of indications.

Previous Arkin investments include UroGen Pharma, Bluejay Therapeutics and Keros Therapeutics.

What they're saying: "We felt that there is opportunity because there's a lack of funding to early-stage companies and technologies," Orbach says.

Follow the money: Arkin raised the new fund from institutional investors, including Phoenix Insurance, Clal Insurance and Amitim Pension Funds.

Zoom in: Arkin also operates a separate fund focused on late-stage biotech deals, such as IPOs, Orbach says.

"We can actually support companies in the early stage, but then when they mature, we also can come with the late-stage funds," Orbach says.

Altogether, Arkin manages more than $2 billion in 12 funds across health, tech and real estate, $600 million of which is focused on biotech.

Zoom out: Other biotech investors also debuted new funds at the end of last year, including Sofinnova Partners, which raised a €650 million fund in November, and Ascenta Capital, which closed a $325 million fund in October.

What we're watching: Biotech stocks had a stellar 2025, outperforming the S&P 500, which could lead more investors to pour money into new biotech funds.

It's possible more will be revealed this week at the JPMorgan Healthcare Conference.

Arkin Capital closes $100M biotech fund

It will focus on early-stage life science companies.

Illustration of a gloved hand with tweezers holding a $100 bill.

Israeli investment firm Arkin Capital has closed its third biotech venture fund at $100 million, managing partner Pini Orbach tells Axios Pro.Why it matters: Funds in the sector largely called 2025 a notoriously difficult fundraising year.

topics

politics-policy

epstein-files

donald-trump

2026-midterm-elections

immigration

behind-the-curtain

race-and-equity

technology

privacy-tech-regulation

automation-and-ai

tiktok-news

big-tech

social-media

cybersecurity

economy

social-security

inflation

tariffs

federal-reserve

jobs

transportation

business

stock-market-news

retail-news

crypto

media

elon-musk

dealmaking

health

rfk-jr

drug-prices

axios-explains-abortion

public-health

world

israel

axios-explains-ukraine

iran

russia

china

energy-climate

nuclear-energy

climate-energy-policy

climate-change

extreme-weather

alternative-energy

electric-vehicles

science

emerging-tech

biomedicine

newsletters

charlotte

boulder

detroit

kansas-city

columbus

austin

dallas

atlanta

washington-dc

nw-arkansas

chicago

indianapolis

nashville

richmond

colorado-springs

houston

san-francisco

seattle

boston

des-moines

salt-lake-city

philadelphia

denver

phoenix

new-orleans

miami

twin-cities

raleigh

san-antonio

portland

san-diego

tampa-bay

cleveland

huntsville

pittsburgh

axios-local

axios-pro

axios-live

the-axios-show

Arkin Capital closes $100M biotech fund

What to read next